单次或重复剂量地塞米松对糖尿病初次全关节置换术后血糖的影响:一项随机对照试验
135例糖尿病初次全关节置换患者随机分为安慰剂组、10 mg地塞米松组和10+10 mg地塞米松组,比较术后空腹血糖和餐后血糖。地塞米松使术后空腹血糖短暂升高但餐后血糖无差异,血糖变异轻度增加但低于临床相关阈值,并发症无差异;术前糖化血红蛋白升高(阈值分别为7.3%和7.0%)而非地塞米松增加空腹血糖≥200 mg/dL或餐后血糖≥260 mg/dL的风险。
要点
- 10 mg或10+10 mg地塞米松使术后空腹血糖短暂升高,餐后血糖无差异。
- 地塞米松组血糖变异轻度增加但低于临床相关阈值,并发症无差异。
- 术前HbA1c升高(阈值7.3%、7.0%)而非地塞米松增加血糖超阈值风险。
核心结论
- 糖尿病全关节置换患者围术期静脉给予10 mg或10+10 mg地塞米松对术后空腹血糖有短暂影响并轻度增加血糖变异,但不是导致血糖升高至临界阈值的危险因素,理论上不增加假体周围感染风险。
- 作者认为应更重视HbA1c而非地塞米松。
研究设计与样本
- 随机对照试验,共纳入135例糖尿病初次全关节置换患者,随机分为三组。
- A组(安慰剂组)围术期静脉注射生理盐水;B组围术期静脉注射10 mg地塞米松;C组围术期静脉注射10+10 mg地塞米松。
- 主要结局为术后空腹血糖和餐后血糖,次要结局包括血糖变异性和炎症标志物,并记录并发症发生率。
主要发现
- 与A组相比,B组术后第0天和第1天空腹血糖更高,C组术后第0天、第1天和第2天空腹血糖更高,餐后血糖无差异。
- B组和C组血糖变异性轻度增加,但仍低于临床相关阈值。
- 三组术后并发症无差异。
- 术前HbA1c升高(阈值分别为7.3%和7.0%)而非地塞米松给药,分别增加空腹血糖≥200 mg/dL或餐后血糖≥260 mg/dL的风险。
关键数值与推荐
- 空腹血糖≥200 mg/dL或餐后血糖≥260 mg/dL的风险因素分析中,术前HbA1c阈值分别为7.3%和7.0%。
- 地塞米松给药未增加空腹血糖≥200 mg/dL或餐后血糖≥260 mg/dL的风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative dexamethasone (DEX) administration in total joint arthroplasty (TJA) has shown better clinical outcomes, but may induce blood glucose (BG) dysregulation and ultimately increase the risk of periprosthetic joint infection (PJI), raising concerns about its safety in diabetic patients. This study aimed to evaluate the effects of single or repeated DEX doses on perioperative BG levels in diabetic patients undergoing TJA. METHODS: A total of 135 patients who had diabetes were randomized into three groups: perioperative intravenous injection of normal saline (Group A, the placebo group), perioperative intravenous injection of 10 mg DEX (Group B), and perioperative intravenous injection of 10 plus 10 mg DEX (Group C). Primary outcomes included postoperative fasting BG (FBG) and postprandial blood glucose (PBG) levels. Secondary outcomes comprised BG variability and inflammatory markers. The incidence of complications was recorded. We also explored the risk factors for FBG levels ≥ 200 mg/dL or PBG levels ≥ 260 mg/dL. RESULTS: Compared to Group A, the FBG levels were higher in Group B on postoperative days (PODs) zero and one and in Group C on PODs zero, one, and two, with no differences in PBG. Elevated preoperative glycosylated hemoglobin A1c (HbA1c) levels (the threshold was 7.3 and 7.0%, respectively), but not DEX administration, increased the risk of FBG levels ≥ 200 mg/dL or PBG levels ≥ 260 mg/dL, respectively. The FBG variability increased slightly in groups B and C but remained below clinically relevant thresholds. No differences were found in postoperative complications among the three groups. CONCLUSIONS: Perioperative intravenous administration of 10 mg or 10 plus 10 mg DEX in diabetic patients undergoing TJA has a transient effect on postoperative FBG levels and slightly increases glycemic variability. However, it is not a risk factor that leads to an elevation in BG levels to a critical threshold and theoretically does not increase the risk of PJI. Greater emphasis should be placed on HbA1c instead of DEX.
引用
- Tang H, Mou P, Liu X, et al. Effects of Single or Repeated Doses of Dexamethasone on Postoperative Glycemia in Patients Who Have Diabetes Mellitus After Primary Total Joint Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2025. PMID: 40541852. doi:10.1016/j.arth.2025.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。